The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour’s TMPRSS2-ERG Fusion Status

Table 2

Overview of the AUCs for the CAPRA score, the CAPRA and PDE4D7, and the CAPRA and PDE4D5/7/9 regression models to predict multiple endpoints in various patient cohorts. The patient cohort that was used for the respective endpoint is indicated including the number of patients with respective follow-up periods. The tested clinical endpoints are given including the number and percentage of the respectively tested events. Note. The CAPRA score is calculated based on [23]; however, as the information on the number of positive biopsy cores was missing for the RP cohort the CAPRA score for this cohort was calculated using patient age, pre-operative PSA, biopsy Gleason score, and clinical stage only. The influence of the missing information on the biopsy cores was very limited as tested on the RP as well as the DB cohort (data not shown).

Patient Cohort	Tested Clinical Endpoint; (post treatment)	# events	CAPRA&PDE4D5/7/9 Score	CAPRA&PDE4D7 Score	CAPRA; Score
			AUC
RP (n=130)	metastases (post-surgery)	8 (6.2%)	0.86	0.82	0.74
DB (n=151)	5-yr PSA recurrence (post-surgery)	45 (19.8%)	0.87	0.82	0.77
DB (n=151)	5-yr start of secondary treatment (post-surgery)	27 (17.9%)	0.82	0.78	0.76
RP (n=220)	10-yr prostate cancer death (post-surgery) (pGleason >6)	21 (11.1%)	0.78	0.78	0.74
RP (n=86)	10-yr prostate cancer death (post-SRT)	18 (20.9%)	0.78	0.76	0.7
RP (n=61)	10-yr prostate cancer death (post-SADT)	17 (27.9%)	0.74	0.72	0.67